Zenas BioPharma (ZBIO) Non-Current Assets (2023 - 2026)

Zenas BioPharma's Non-Current Assets history runs 4 years deep, the most recent figure standing at $17.5 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 9.77% year-over-year to $17.5 million; the TTM figure through Mar 2026 stood at $89.8 million (up 87.04% YoY), while the FY2025 annual figure was $32.5 million, up 131.18% from the prior year.
• Non-Current Assets was $17.5 million for Q1 2026 at Zenas BioPharma, down from $32.5 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $32.5 million in Q4 2025 to a low of $8.4 million in Q4 2023.
• Historically, Non-Current Assets has averaged $17.2 million across 4 years, with a median of $15.2 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Assets jumped 162.85% in 2025, then climbed 9.77% in 2026.
• A 4-year view of Non-Current Assets shows it stood at $8.4 million in 2023, then jumped by 67.68% to $14.0 million in 2024, then soared by 131.18% to $32.5 million in 2025, then slumped by 46.05% to $17.5 million in 2026.
• The last three Non-Current Assets figures came in at $17.5 million (Q1 2026), $32.5 million (Q4 2025), and $25.4 million (Q3 2025), per Business Quant data.